Update on Biologics for Psoriasis in Clinical Practice

Biologics have impacted the clinical management of moderate to severe psoriasis. This review article highlights new data findings from phase 3 clinical trials (N=8) published between May 2020 and February 2021. Data on the efficacy of US Food and Drug Administration-approved biologics for treating psoriasis affirms durable skin clearance in the presence of comorbidities and after treatment gaps. This article aims to provide clinicians with up-to-date knowledge on biologic performance focusing on skin disease clearance, time to skin disease clearance, loss of response and relapse, and treatment-emergent adverse events (TEAEs). Recent trial data in this review focus on treatment with IL-17A inhibitors and IL-23 inhibitors.